Tags

Type your tag names separated by a space and hit enter

Parkinson's disease.
CMAJ. 1989 Mar 01; 140(5):507-14.CMAJ

Abstract

In Parkinson's disease there is degeneration of neurons in the substantia nigra, with consequent depletion of the neurotransmitter dopamine. The triad of tremor, rigidity and bradykinesia is the clinical hallmark. Drugs currently used for palliative therapy fall into three categories: anticholinergic agents, dopamine precursors (levodopa combined with extracerebral decarboxylase inhibitors) and artificial dopamine agonists. It has been argued, on theoretical grounds, that some drugs slow the progress of Parkinson's disease, although no firm evidence has supported this. Treatment must be individualized, and more than one type of drug can be given concurrently after a careful build-up in dosage. We review the adverse effects of various drugs and consider new developments such as slow-release preparations, selective D-1 and D-2 agonists and transplants of dopaminergic cells into the brain. The treatment of Parkinson's disease can be demanding, rewarding and sometimes frustrating, but it remains a most challenging exercise in pharmacotherapy.

Authors+Show Affiliations

Department of Medicine, University Hospital, Vancouver, BC.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

2563667

Citation

Wolters, E C., and D B. Calne. "Parkinson's Disease." CMAJ : Canadian Medical Association Journal = Journal De l'Association Medicale Canadienne, vol. 140, no. 5, 1989, pp. 507-14.
Wolters EC, Calne DB. Parkinson's disease. CMAJ. 1989;140(5):507-14.
Wolters, E. C., & Calne, D. B. (1989). Parkinson's disease. CMAJ : Canadian Medical Association Journal = Journal De l'Association Medicale Canadienne, 140(5), 507-14.
Wolters EC, Calne DB. Parkinson's Disease. CMAJ. 1989 Mar 1;140(5):507-14. PubMed PMID: 2563667.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Parkinson's disease. AU - Wolters,E C, AU - Calne,D B, PY - 1989/3/1/pubmed PY - 1989/3/1/medline PY - 1989/3/1/entrez SP - 507 EP - 14 JF - CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne JO - CMAJ VL - 140 IS - 5 N2 - In Parkinson's disease there is degeneration of neurons in the substantia nigra, with consequent depletion of the neurotransmitter dopamine. The triad of tremor, rigidity and bradykinesia is the clinical hallmark. Drugs currently used for palliative therapy fall into three categories: anticholinergic agents, dopamine precursors (levodopa combined with extracerebral decarboxylase inhibitors) and artificial dopamine agonists. It has been argued, on theoretical grounds, that some drugs slow the progress of Parkinson's disease, although no firm evidence has supported this. Treatment must be individualized, and more than one type of drug can be given concurrently after a careful build-up in dosage. We review the adverse effects of various drugs and consider new developments such as slow-release preparations, selective D-1 and D-2 agonists and transplants of dopaminergic cells into the brain. The treatment of Parkinson's disease can be demanding, rewarding and sometimes frustrating, but it remains a most challenging exercise in pharmacotherapy. SN - 0820-3946 UR - https://www.unboundmedicine.com/medline/citation/2563667/Parkinson's_disease_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/2563667/ DB - PRIME DP - Unbound Medicine ER -